Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 11/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 9/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732421 | 0.87 | PLAU (0.45) | PLAUERN1FYNFLT3AAK1 | |
| SCHEMBL731170 | 0.86 | PLAU (0.39) | PLAUFGFR2ERN1FYNFLT3 | |
| SCHEMBL730668 | 0.80 | KDM4E (0.39) | PLAUFGFR2AAK1BRD4TTK | |
| SCHEMBL730845 | 0.75 | ALDH1A1 (0.42) | — | |
| SCHEMBL4274681 | 0.69 | HSD17B10 (0.32) | — | |
| SCHEMBL732364 | 0.68 | AAK1 (0.41) | PLAUERN1FYNAAK1BRD4 | |
| SCHEMBL733242 | 0.67 | CNR2 (0.55) | PLAUFGFR3FGFR2ERN1AAK1 | |
| SCHEMBL24731373 | 0.67 | BRD4 (0.45) | FGFR3FGFR1FGFR2FGFR4PDK2 | |
| SCHEMBL731007 | 0.66 | TSHR (0.49) | PLAUFGFR3FGFR1FGFR2FGFR4 | |
| SCHEMBL27316670 | 0.66 | PDK2 (0.46) | FGFR3FGFR1FGFR2FGFR4ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120569-B1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-2120569-A2 | SPIROCHROMANON DERIVATIVES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | AKR1C3, CBR3, AKR1C4 | PLAU 4523/4885FGFR3 1130/4885FGFR1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.